RVMD — Revolution Medicines Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets an… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$154.89
Market Cap$31.96B
Float194.2M
Shares Outstanding212.6M
Price/Sales (TTM)9,035.10
vs. Analyst Target+19.1% to analyst PT
Revenue (TTM)$742,000
Dividend RateNone
Analyst Target Price$184.45 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $43.0M -$108M $43.0M -$102M
2021 $29.4M -$187M $29.4M -$180M
2022 $35.4M -$249M $35.4M -$249M
2023 $11.6M -$436M $11.6M -$478M
2024 N/A -$600M -$592M -$678M
2025 N/A -$1.13B -$16.6M -$1.09B

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$248M
Sep 2025 N/A -$305M
Dec 2025 N/A -$365M
Mar 2026 N/A -$454M

Ownership & Float

Insider Ownership1.9%
Institutional Ownership95.4%
Short Float6.6%
% of All Funds Holding5.84%
Number of Funds Holding480

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$130.54Near-term / short-term trend
Weekly40-Week SMA$89.87Medium-term trend
Weekly80-Week SMA$65.22Cyclical trend (business cycle)
Weekly200-Week SMA$44.21Secular trend (multi-year)
Monthly10-Month SMA$89.61Near-term monthly trend
Monthly20-Month SMA$66.21Medium-term monthly trend
Monthly40-Month SMA$48.62Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$99.00 support 1.59x 0 months ago
$81.00 support 2.12x 3 months ago
$59.00 support 1.09x 5 months ago
$47.00 support 1.22x 6 months ago
$38.00 support 1.18x 7 months ago

Historical Earnings Reactions (26 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -1.12% -1.05% 30.77% 9.54% -11.71%
1 Day 0.73% -0.39% 46.15% 15.85% -10.97%
1 Week 1.77% 0.44% 50.00% 21.18% -9.23%
2 Weeks 0.69% 0.65% 50.00% 19.98% -18.68%
1 Month 4.89% 7.19% 68.00% 32.06% -23.19%

Next earnings: July 25, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.05% 50.0% 294
Tuesday 0.38% 50.3% 326
Wednesday 0.26% 53.4% 324
Thursday -0.04% 47.8% 316
Friday 0.28% 52.2% 316

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 95.4%

Insider Transactions — Smart Summary

Total insider ownership: 1.9%

12-Month Insider Activity Summary

Total Filings45
Net Value-$54.9M
Net Shares Change-79,967
% of Float-0.0%
C-Suite Filings45
Clusters Detected7

Key Insiders

NameTitleNet ValueFilingsActivity
GOLDSMITH MARK A President and Chief Executive Officer -$24.0M 4 N/A
Horn Margaret A Chief Operating Officer -$828,252.126 2 N/A
Anders Jack Chief Financial Officer -$513,158.143 2 N/A
Cislini Jeff General Counsel -$498,373.943 2 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-06-18 – 2025-06-23 7 6 -$1.2M 7 C-suite
2025-09-04 – 2025-09-18 8 6 -$6.7M 8 C-suite
2025-10-15 – 2025-10-20 3 3 -$2.3M 3 C-suite
2025-11-12 – 2025-11-26 7 3 -$10.2M 7 C-suite
2025-12-18 – 2025-12-18 5 5 -$2.4M 5 C-suite
2026-01-09 – 2026-01-23 3 3 -$5.3M 3 C-suite
2026-03-19 – 2026-03-26 8 8 -$5.5M 8 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-03 GOLDSMITH MARK A President and Chief Executive Officer -$3.5M Transaction at $68.87, now +124.9%
2026-03-19 GOLDSMITH MARK A President and Chief Executive Officer -$1.3M Transaction at $99.48, now +55.7%
2026-03-19 Horn Margaret A Chief Operating Officer -$455,918.673 Transaction at $99.48, now +55.7%
2026-03-19 Cislini Jeff General Counsel -$291,890.116 Transaction at $98.68, now +57.0%
2026-03-19 Anders Jack Chief Financial Officer -$273,869.541 Transaction at $99.48, now +55.7%
2025-12-18 Cislini Jeff General Counsel -$206,483.827 Transaction at $76.82, now +101.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Revolution Medicines Inc (RVMD) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for RVMD on Trend Edge →